References
- 1. Than NN, Oo YH. A Concise Review of Autoimmune Liver Diseases. Pathogenesis, Clinical Aspects and Therapy of Specific Autoimmune Diseases. IntechOpen. 2015. DOI:10.5772/60520.10.5772/60520
- 2. Hubers LM, Wenniger LJM, Doorenspleet ME. IgG-4 Associated Cholangitis: A Comprehensive Review. Clinic Rev Allerg Immunol 2015; 48, 198–206. DOI:10.1007/s12016-014-8430-2.10.1007/s12016-014-8430-2
- 3. Jepsen P, Gronbaek L, Vilstrup H. Worldwide incidence of Autoimmune Liver Disease. Dig Dis 2015; 33(suppl 2):2-12. DOI:10.1159/000440705.10.1159/000440705
- 4. Mehta N. Drug-Induced Hepatotoxicity. Medscape 2019; https://emedicine.medscape.com/article/169814-overview.
- 5. Talwani R, Gilliam BL, Howell, C. Infectious Diseases and the Liver. Clin Liver Dis 2011; 15(1), 111–130. DOI: 10.1016/j.cld.2010.09.002.10.1016/j.cld.2010.09.002
- 6. Sharma B, John S. Nonalcoholic Steatohepatitis. StatPearls. Treasure Island: StatPearls Publishing 2020; https://www.ncbi.nlm.nih.gov/books/NBK470243/.
- 7. Kumar A, Riley CA. Inherited Liver Diseases in Adults. West J Med 1995; 163(4), 382-386. PMCID:PMC1303145.
- 8. Shimizu, Y. Liver in systemic disease. World J Gastroenterol 2008; 14(26), 4111–4119. DOI: 10.3748/wjg.14.4111.10.3748/wjg.14.4111
- 9. Weisbart RH, Colburn K. Effect of Corticosteroids on Serum Antinuclear Antibodies in Mac. Immunopharmacology. 1984. 8(2): 97–101. DOI: 10.1016/0162-3109(84)90048-1. PMID: 6334672.10.1016/0162-3109(84)90048-1
- 10. Anaya JM, Villarraga AR, Carrasco MG. The Autoimmune Tautology. Polyautoimmunity and Familial Autoimmunity to the Autoimmune Genes. Autoimmune Disease 2012; 2012. Article ID: 297193. DOI:10.1155/2012/297193.10.1155/2012/297193336280722666553
- 11. Anaya JM. The diagnosis and clinical significance of polyautoimmunity. Autoimmun Rev 2014; 13(4–5):423–426. DOI:10.1016/j.autrev. 2014.01.049.
- 12. Siriwardhane T, Krishna K, Ranganathan V, et al. Significance of Anti-TPO as an Early Predictive Marker in Thyroid Disease. Autoimmune Diseases 2019; 2019. Article ID: 1684074. DOI:10.1155/2019/1684074.10.1155/2019/1684074669935831467701
- 13. Washington M. Autoimmune liver disease: Overlap and outliers. Modern Pathology 2007; 20(suppl 1): S15-30. DOI:10.1038/modpathol.3800684.10.1038/modpathol.380068417486048
- 14. Trivedi PJ, Hirschfield GM. Treatment of auto-immune liver disease: current and future therapeutic options. Ther Adv Chronic Dis 2013; 4(3): 119–141. DOI: 10.1177/2040622313478646.10.1177/2040622313478646362975023634279
- 15. Goode EC, Rushbrook SM. A review of the medical treatment of primary sclerosing cholangitis in the 21st century. Ther Adv Chronic Dis 2016; 7(1): 68–85. DOI: 10.1177/2040622315605821.10.1177/2040622315605821470742726770670
- 16. Maestranzi S, Przemioslo R, Mitchell H. The effect of benign and malignant liver disease on the tumour markers CA19-9 and CEA. Ann Clin Biochem 1998; 35: 99–103. DOI: 10.1177/000456329803500113.10.1177/0004563298035001139463746
- 17. Keklik M, Sivgin S, Kaynar L. Treatment with plasma exchange may serve benefical effect in patients with severe hyperbilirubinemia: A single center experience. Transfusion and apheresis science: official journal of the World Apheresis Association: official journal of the European Society for Haemapheresis 2013; 48: 323–326 DOI: 10.1016/j.transci.2013.04.009.10.1016/j.transci.2013.04.00923602141